PRTC - PureTech Health plc
| Previous Close | 27.50 |
| Open | 26.89 |
| Bid | 23.42 x 1400 |
| Ask | 45.20 x 900 |
| Day's Range | 26.89 - 26.91 |
| 52 Week Range | 18.15 - 38.90 |
| Volume | |
| Avg. Volume | 614 |
| Market Cap | 747.054M |
| Beta (5Y Monthly) | 0.81 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.80 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 70.00 |
Business WirePureTech to Present at the Jefferies Healthcare Conference
BOSTON, May 24, 2023--PureTech to Present at the Jefferies Healthcare Conference
Business WirePureTech Founded Entity Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week
BOSTON, May 09, 2023--PureTech Founded Entity Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week
Business WirePureTech Founded Entity Akili Announces Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili’s EndeavorRx® Video Game-Based Therapeutic
BOSTON, May 04, 2023--PureTech Founded Entity Akili Announces Topline Results of the STARS-ADHD-Adult Clinical Trial
- Thomson Reuters StreetEvents
Full Year 2023 PureTech Health PLC Earnings Call
Full Year 2023 PureTech Health PLC Earnings Call
Business WirePureTech Founded Entity Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies
BOSTON, April 25, 2023--PureTech Founded Entity Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies
Business WirePureTech Founded Entity Vedanta Biosciences Publishes Phase 2 Results in the Journal of the American Medical Association and Presents at ECCMID
BOSTON, April 17, 2023--PureTech Founded Entity Vedanta Biosciences Publishes Phase 2 Results in the Journal of the American Medical Association and Presents at ECCMID
Business WirePureTech Health: Notice of Results
BOSTON, April 13, 2023--PureTech Health: Notice of Results
GlobeNewswireRoyalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million
Royalty Pharma has acquired an interest in PureTech’s royalty in Karuna Therapeutics’ KarXT; Royalty Pharma and PureTech will share in royalties above certain annual sales thresholdsPureTech retains its current equity stake in Karuna in addition to milestone payments and 20% of sublicense revenues due to PureTechTransaction provides further non-dilutive capital for PureTech’s growing and rapidly advancing Wholly Owned Pipeline, with five clinical-stage candidates expected by the end of 2023 NEW
Business WirePureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million
BOSTON & NEW YORK, March 23, 2023--PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million
Business WirePureTech to Present at the Barclays Global Healthcare Conference
BOSTON, March 01, 2023--PureTech to Present at the Barclays Global Healthcare Conference
Business WirePureTech Founded Entity Sonde Health and Massachusetts General Hospital Selected for National Institute on Aging Study to Examine Use of Voice in Remote Detection and Monitoring of Mild Cognitive Impairment Including Frontotemporal Disorders (FTD)
BOSTON, February 27, 2023--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Sonde Health, a health technology company committed to bringing accessible health monitoring to everyone, in conjunction with the Massachusetts General Hospital (MGH) Frontotemporal Disorders (FTD) Unit, has been selected by the Massachusetts Artificial Intelligence and Technology Center for Connected Care in Aging
Business WirePureTech to Advance LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders and Postpartum Depression
BOSTON, February 14, 2023--PureTech to Advance LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders and Postpartum Depression
Business WirePureTech to Present at the SVB Securities Global Biopharma Conference
BOSTON, February 01, 2023--PureTech to Present at the SVB Securities Global Biopharma Conference
Business WirePureTech Provides End of Year Report on Key Progress
BOSTON, December 22, 2022--PureTech Provides End of Year Report on Key Progress
Business WirePureTech’s LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerability and GABAA Receptor Target Engagement in Healthy Volunteers
BOSTON, December 19, 2022--PureTech’s LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerability and GABAA Receptor Target Engagement in Healthy Volunteers
Business WirePureTech to Present at 41st Annual J.P. Morgan Healthcare Conference
BOSTON, December 13, 2022--PureTech to Present at 41st Annual J.P. Morgan Healthcare Conference
Business WirePureTech Presents Data for LYT-200 Targeting Galectin-9 in Preclinical Leukemia Cancer Models at the 64th American Society of Hematology (ASH) Annual Meeting
BOSTON, December 12, 2022--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today shared new data supporting the clinical potential of LYT-200, a fully human monoclonal antibody (mAb) designed to inhibit the activity of galectin-9, as a therapeutic agent for the treatment of leukemia. The data were shared in a scientific poster presented at the American Soci
Business WirePureTech Founded Entity Sonde Health Raises $19.25 Million Series B for Voice-Based Health Monitoring
BOSTON, December 09, 2022--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Sonde Health, a health technology company committed to bringing accessible health monitoring to everyone, announced it has raised a $19.25 million Series B investment round with a strong group of financial and strategic investors.
Business WirePureTech Announces New Therapeutic Candidate, LYT-310, an Oral Form of Cannabidiol (CBD) Leveraging PureTech’s Glyph™ Platform
BOSTON, November 30, 2022--PureTech Announces New Therapeutic Candidate, LYT-310, an Oral Form of Cannabidiol (CBD) Leveraging PureTech’s Glyph™ Platform
Business WirePureTech to Present at Two Upcoming Investor Conferences
BOSTON, November 17, 2022--PureTech to Present at Two Upcoming Investor Conferences
- Business Wire
PureTech to Present at the Jefferies London Healthcare Conference
BOSTON, November 09, 2022--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today announced that Daphne Zohar, Founder and Chief Executive Officer, and Julie Krop, M.D., Chief Medical Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 16, 2022, at 3:50pm GMT / 10:50am EST. A webcast of the presen
Business WirePureTech to Present at the Credit Suisse 31st Annual Healthcare Conference
BOSTON, November 01, 2022--PureTech to Present at the Credit Suisse 31st Annual Healthcare Conference
Business WirePureTech to Present at the Morgan Stanley Global Healthcare Conference
BOSTON, September 08, 2022--PureTech to Present at the Morgan Stanley Global Healthcare Conference
Business WirePureTech Presents Data for LYT-100 (Deupirfenidone) Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at European Respiratory Society International Congress 2022
BOSTON, September 06, 2022--PureTech Presents Data for LYT-100 Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at ERS International Congress 2022
Simply Wall St.Some Analysts Just Cut Their PureTech Health plc (LON:PRTC) Estimates
Market forces rained on the parade of PureTech Health plc ( LON:PRTC ) shareholders today, when the analysts downgraded...